Description: A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies
Mechanism of Action: Anti-CD73 (Sym024) with or without Anti-PD-1 (Sym021). CD73 is cell surface bound enzyme which converts AMP to adenosine. In tumor microenvironment extracellular adenosine decreases T cell responses.
Target Patient Population: NSCLC (Adeno), Pancreatic, Cholangiocarcinoma, Metastatic Colorectal, Gastric, Esophageal, Mesothelioma and Squamous cell Head & Neck
Study Design: Both Drugs are given IV every 2 weeks of a 28 day cycle